ATAI adds MD­MA biotech to grow­ing list of psy­che­del­ic mak­ers; Aca­dia adds $52.5M up­front pain buy­out

For years, the biggest push in psy­che­del­ic drug de­vel­op­ment has been around MD­MA, a par­ty drug long thought to have po­ten­tial ben­e­fits for pa­tients with PTSD. Rick Doblin, for years psy­che­del­ic ther­a­py’s most promi­nent ad­vo­cate and fundrais­er, and his non-prof­it, MAPS, have raised mil­lions to ad­vance clin­i­cal tri­als, most re­cent­ly rais­ing $30 mil­lion to com­plete a Phase III study in vet­er­ans.

But ATAI, the Ger­man-born biotech that has quick­ly be­come the most promi­nent pri­vate pro­mot­er and dri­ver of psy­che­del­ic ther­a­py, still thinks they have some­thing to of­fer. Yes­ter­day, the port­fo­lio an­nounced their lat­est sub­sidiary: Em­path­Bio.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.